중추성 성조숙증 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the central precocious puberty market size is expected to increase from USD 1.71 billion in 2025 to USD 1.82 billion in 2026 and reach USD 2.56 billion by 2031, growing at a CAGR of 8.53% over 2026-2031.

This report is Segmented by Drug Class (Leuprolide Acetate, Triptorelin, Histrelin, Nafarelin), Distribution Channel (Hospital, Retail, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Central Precocious Puberty Market Trends and Insights

Rising Incidence Linked to Pediatric Obesity & Endocrine-Disruptor Exposure

Childhood obesity is linked to faster activation of the hypothalamic pituitary gonadal axis, and reported CPP prevalence in girls with obesity reached 48% versus 8.73% in normal-weight cohorts. Elevated leptin and kisspeptin signaling appear to contribute to earlier thelarche and menarche in these populations, which sustains a steady inflow of patients into the central precocious puberty market. Low-dose endocrine-disrupting chemical mixtures also correlate with gut microbiome changes, including reported decreases in Lactobacillus of 40% in human studies and 58% in rodent models. Modeling work suggested that gut-brain axis mediators explained 68% of internal variance for early puberty risk at low experimental doses, which raises long-horizon incidence expectations independent of access to care. As regulators continue to reassess exposure limits for endocrine-active substances, care pathways for earlier screening and treatment are likely to remain a planning priority for the central precocious puberty market.

Uptake Of Long-Acting GnRH-Analog Depots & Implants

Six-month depot formats are reducing visit frequency and improving adherence, supported by Phase III data showing 94% of pediatric patients on leuprolide mesylate 42 mg achieved LH suppression below 4 mIU/mL at Week 24 with statistical significance. Annual dosing is moving closer, with a 12 month triptorelin formulation completing Phase III enrollment across multiple countries and targeting a 2026 U.S. filing. As families reduce clinic visits relative to monthly schedules, indirect costs and school or work absences also fall, which supports steady adherence over multi-year courses of therapy in the central precocious puberty market. Manufacturing precision for uniform PLGA microspheres remains a limitation in scaling supply, which concentrates risk and makes single-site interruptions more consequential for patient access . These delivery platform shifts are now core to competitive strategies, since pharmacologic mechanisms across GnRH agonists are similar and differentiation hinges on interval, consistency, and product logistics in the central precocious puberty market.

Supply-Chain Gaps for Biodegradable Microsphere Injectables

Documented shortages of depot triptorelin in the United Kingdom from March 2025 through January 2026 illustrate the fragility of PLGA microsphere supply lines, with Tier 2 disruption status underscoring the medium impact on patients and providers. Concentrated manufacturing and complex particle engineering increase the chance that a single facility issue can affect many clinics at once in the central precocious puberty market. Parallel availability of alternative GnRH analogs during this period mitigated some of the access risks, yet switching can complicate scheduling and monitoring across health systems. These events highlight the operational value of multi-product formularies and cross-training among pharmacy teams, which reduces friction when shortages arise. The underlying dynamic supports strategic investments that diversify sources and build redundancy for critical components in the central precocious puberty market.

Other drivers and restraints analyzed in the detailed report include:

1. Wider Reimbursement Expanding Treatment Access
2. Improved Ultrasensitive LH Assays Boosting Early Diagnosis
3. Limited CPP Awareness Among Primary-Care Physicians

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Leuprolide acetate secured 45.24% of the central precocious puberty market share in 2025, reflecting the depth of the Lupron Depot franchise across multiple dosing intervals. Triptorelin is projected to grow at a 7.49% CAGR through 2031 as semiannual formulations and the first annual injectable candidate advance, which is consistent with provider preferences for longer intervals and streamlined clinic schedules in the central precocious puberty market. Histrelin, delivered as a surgically implanted 50 mg device, faced revenue pressure in late 2024 as payers shifted to injectable depots and families weighed the trade-offs of minor procedures versus office-based injections. Nafarelin nasal spray continues to serve a narrow group of patients who require a non-injectable route, although its frequent dosing reduces suitability for many families in the central precocious puberty market. Across these options, choice is shaped by dosing cadence, predictability of LH suppression at interval endpoints, and the ease of coordinating refills and visits across busy pediatric practices.

In late 2025, a six-month leuprolide mesylate formulation met its primary endpoint in Phase III pediatric CPP with 94% LH suppression at Week 24, which would add a third semiannual leuprolide option if approved. Portfolio breadth that spans one month to six months has helped incumbents retain brand familiarity among pediatric endocrinologists, although longer-acting products are capturing more starts and switches as care teams aim to reduce missed doses in the central precocious puberty market. Annual triptorelin would extend that logic further by compressing the visit schedule to a single implant-style appointment per year if outcomes prove noninferior, which could shift share from quarterly and semiannual regimen. Evidence reviews also suggest interest in combination care, where GnRH analogs with growth hormone can improve height outcomes in select cases, although costs and monitoring needs limit widespread use in the central precocious puberty industry.

Geography Analysis

North America retained 43.11% of the central precocious puberty market share in 2025, supported by broad coverage in major plans, clear testing criteria, and multiple long-acting GnRH analogs available to pediatric endocrinologists. U.S. payer policies have specified accepted assay types, thresholds for LH results, and quantity limits aligned to dosing intervals, which improves predictability in treatment approvals and renewals for families and providers. In Canada, a six-month 45 mg leuprolide strength received approval in late 2025, adding to the set of long-acting options across North America and reinforcing the role of extended intervals in routine practice in the central precocious puberty market. Clinicians are also responding to safety signals emerging in the literature, including a meta-analysis that observed higher PCOS risk in treated girls relative to untreated cohorts, which is informing counseling and follow-up discussions with families. The regional ecosystem of specialty pharmacies, children's hospitals, and payer formularies supports timely care, even as supply stewardship remains important in the central precocious puberty market.

Asia Pacific is the fastest-growing region at an expected 8.24% CAGR from 2026 to 2031, helped by increasing diagnostic capacity, expanding specialist coverage, and rising awareness among families seeking early interventions. A comprehensive meta-analysis that aggregated studies across China, South Korea, and Thailand reflected active clinical research and a growing base of patients entering care pathways, with efficacy influenced by age at onset and timeliness of initiation. As longer-acting formats scale globally, providers in APAC are prioritizing dosing intervals that match clinic resources and family preferences, which supports steady adoption in the central precocious puberty market. Multi-country pediatric trials for annual triptorelin underscore the region's increased participation in late-stage development and signal the demand for delivery models that minimize clinic visits while preserving suppression targets. Continued investments in lab infrastructure and teleconsult coverage are expected to improve referral pathways and reduce diagnostic delays in the central precocious puberty market.

Europe shows steady adoption at mid single-digit growth, anchored by established pediatric endocrinology centers, HTA processes, and country-level reimbursement frameworks that support long-acting GnRH analogs. Ipsen reported strong 2025 performance across therapeutic areas and guided to sustained margin strength in 2026, which reflects underlying demand for rare disease assets and the capability to maintain supply at scale. Supply monitoring remains a regional focus following U.K. notifications of triptorelin depot shortages that persisted into early 2026, which highlighted the need for contingency stocks and alternative regimens during constrained periods in the central precocious puberty market. In the Middle East and Africa and in South America, access is evolving from smaller bases as specialty pharmacy networks, diagnostic capacity, and public payer coverage expand at different speeds, which keeps the share modest but rising in the central precocious puberty market.

1. Abbvie
2. Accord BioPharma (Intas)
3. Arbor Pharmaceuticals
4. Cipla
5. Debiopharm Group
6. Endo International
7. Ferring Pharmaceuticals
8. Hanmi Pharmaceutical
9. Ipsen
10. Lupin
11. Novo Nordisk
12. Pfizer
13. Sandoz Group
14. Sanofi
15. Sun Pharmaceuticals Industries
16. Taro Pharmaceuticals
17. Teva Pharmaceutical Industries
18. Tolmar Pharmaceuticals Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence Linked to Pediatric Obesity & Endocrine-Disruptor Exposure
  • 4.2.2 Uptake Of Long-Acting GnRH-Analog Depots & Implants
  • 4.2.3 Wider Reimbursement Expanding Treatment Access
  • 4.2.4 Improved Ultrasensitive LH Assays Boosting Early Diagnosis
  • 4.2.5 Tele-Endocrinology Platforms Increasing Specialist Reach
  • 4.2.6 Pipeline Oral GnRH Antagonists Promising Needle-Free Therapy
• 4.3 Market Restraints
  • 4.3.1 High Annual Therapy Cost in Low-Income Regions
  • 4.3.2 Limited CPP Awareness Among Primary-Care Physicians
  • 4.3.3 Safety Concerns: Bone-Density Loss & Intracranial Hypertension
  • 4.3.4 Supply-Chain Gaps for Biodegradable Microsphere Injectables
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces

5 Market Size & Growth Forecasts

• 5.1 By Drug Class
  • 5.1.1 Leuprolide Acetate
  • 5.1.2 Triptorelin
  • 5.1.3 Histrelin
  • 5.1.4 Nafarelin
• 5.2 By Distribution Channel
  • 5.2.1 Hospital Pharmacies
  • 5.2.2 Retail Pharmacies
  • 5.2.3 Online Pharmacies
• 5.3 By Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 India
    • 5.3.3.3 Japan
    • 5.3.3.4 South Korea
    • 5.3.3.5 Australia
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East & Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East & Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 AbbVie Inc.
  • 6.3.2 Accord BioPharma (Intas)
  • 6.3.3 Arbor Pharmaceuticals LLC
  • 6.3.4 Cipla Ltd.
  • 6.3.5 Debiopharm Group
  • 6.3.6 Endo International plc
  • 6.3.7 Ferring Pharmaceuticals A/S
  • 6.3.8 Hanmi Pharmaceutical
  • 6.3.9 Ipsen SA
  • 6.3.10 Lupin Ltd.
  • 6.3.11 Novo Nordisk A/S
  • 6.3.12 Pfizer Inc.
  • 6.3.13 Sandoz AG
  • 6.3.14 Sanofi SA
  • 6.3.15 Sun Pharmaceutical Industries Ltd.
  • 6.3.16 Taro Pharmaceuticals
  • 6.3.17 Teva Pharmaceutical Industries Ltd.
  • 6.3.18 Tolmar Pharmaceuticals Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment